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Abstract
We describe a computational protocol to aid the design of small molecule and peptide drugs that 
target protein-protein interactions, particularly for anti-cancer therapy. To achieve this goal, we 
explore multiple strategies, including finding binding hot spots, incorporating chemical similarity 
and bioactivity data, and sampling similar binding sites from homologous protein complexes. We 
demonstrate how to combine existing interdisciplinary resources with examples of semi-automated 
workflows. Finally, we discuss several major problems, including the occurrence of drug-resistant 
mutations, drug promiscuity, and the design of dual-effect inhibitors.
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1 Introduction
Protein-protein interactions (PPI) are remarkably complex and diverse. They form intricate 
interaction networks where some proteins (so-called hubs) make connections to many other 
proteins. Despite the diversity and complexity, there are recurrent motifs in the PPI networks 
and protein-protein binding sites [1, 2]. PPI interaction networks can be perturbed by 
differential gene expression and disease mutations [3–6] and a lot of efforts have been 
undertaken to study how signal flow in the networks is altered by these factors and how 
drugs can reestablish the intricate balance. Targeting of PPIs for therapeutic intervention is 
very challenging because of the size and shape of their binding interfaces, e.g., planar 
interfaces lacking binding pockets, the difficulty to construct a functional assay to screen out 
affected interactions. Nevertheless, for the last several years there has been a considerable 
interest in PPI drug targets. Furthermore, many existing drugs have promiscuous effects on 
interaction pathways affecting highly connected protein hubs, while PPI inhibitors can be 
designed to achieve highly specific drug binding to a target protein complex. The success 
stories include the design of inhibitors of bromo-domains [7], Bax-BclXL [8], p53-MDM2 
[9], and VEGF receptor [10]. The up-to-date database 2P2Idb v.2 contains 27 structurally 
characterized protein-protein complexes and 274 protein-inhibitor complexes with 242 
unique small molecule inhibitors [11].
Predicting the phenotypic effects of mutations and molecular mechanisms of drugs cannot 
be achieved without the detailed knowledge of cellular pathways, interaction networks, and 
PPI binding interfaces. Studies on PPI binding site properties go back several decades, and 
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some of them reported an extensive similarity between protein interfaces even in the absence 
of sequence or structure similarity between proteins [12–15]. Since the current coverage of 
the human proteome with protein structural complexes remains limited, and the number of 
novel PPI binding sites in the PDB database grows slower than the number of protein 
complexes [16, 17], different computational methods have been proposed to close this gap. It 
has been shown that protein interactions and binding sites for human complexes can be 
predicted from homologous protein structural complexes of another species [18–20]. Such 
an inference approach may be supported by a recent work that examined the growth 
dynamics and evolutionary roots of PPI binding sites and found that a majority of binding 
sites could be traced back to the universal common ancestor of all cellular organisms [16].
There are several challenges in the structural design of PPI inhibitors. First, the inhibitor 
should bind relatively strongly to the protein target. This is achieved by mimicking the 
interactions between two proteins, especially those interactions between residues that 
contribute most to the binding energy, so-called binding hot spots. Second, many anti-cancer 
therapies are prone to acquired drug resistance which is a major challenge in cancer 
treatment. Therefore, the designed inhibitor (peptide or small molecule) should retain its 
properties, even if two interacting target proteins undergo extensive selection in the tumor to 
eliminate binding to these inhibitors while retaining binding between the two proteins. The 
latter task can be accomplished by inhibitor design along with in-silico mutagenesis. Finally, 
the inhibitors should be active with respect to not only the proposed PPI targets but also with 
respect to their paralogs. We illustrate the PPI inhibitor design principles using the p53-
MDM2 interaction as an example.
2 Materials
2.1 Online Resources
1. IBIS https://www.ncbi.nlm.nih.gov/Structure/ibis/ibis.cgi [21, 22]; IBIS API 
https://www.ncbi.nlm.nih.gov/research/ibis-api/.
2. PubChem BioAssay (https://pubchem.ncbi.nlm.nih.gov) [23, 24].
3. MutaBind (https://www.ncbi.nlm.nih.gov/research/mutabind/) [25, 26].
4. NCI drug dictionary (http://www.cancer.gov/publications/dictionaries/cancer-
drug) [27].
5. Drug sensitivity in cancer (http://www.cancerrxgene.org/translation/Drug).
6. 2P2Idb database v2 (http://2p2idb.cnrs-mrs.fr/) [11].
7. Binding DB (https://www.bindingdb.org/bind/) [28].
8. SAAMBE and HotRegion (http://prism.ccbb.ku.edu.tr/hotregion/) [29, 30].
2.2 Software
1. KNIME (https://www.knime.org).
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3 Methods
3.1 Practical Challenges in Cancer Drug Design: p53-MDM2 Inhibitors
Cytotoxicity of cancer drugs may lead to genomic instability and consequently to the 
activation of the p53 tumor suppressor. E3 ubiquitin-protein ligase (MDM2) endogenously 
inhibits p53, and the disruption of an interaction between the p53 transactivation domain and 
MDM2 leads to the activation of p53. MDM2 negatively regulates the p53 pathways and is 
often overexpressed in tumor cells. Different small molecule and stapled peptide-based 
drugs have been designed to inhibit the p53-MDM2 interaction [31, 32]. One of the very 
well-studied small molecule p53-MDM2 inhibitors is Nutlin-3 that exhibits anti-cancer 
effects even in those cells that do not express functional p53 via mechanisms involving p73 
and E2F1 activation [33]. Other p53-MDM2 inhibitors are currently under clinical trials. 
Stapled peptides that inhibit protein-protein interactions are an emerging class of drugs since 
they can better resist the cancer clonal selection leading to drug resistance. Their 
effectiveness can be explained by a more extensive interface between the peptides and 
proteins compared to small molecules, so that a larger number of acquired drug-resistant 
mutations on the p53-MDM2 interface can be targeted.
3.2 Exploring Binding Interfaces of Homologous Protein Complexes
To find protein complexes that can potentially be targeted by small molecules, one can 
examine a superposition of protein-protein and protein-small molecule binding interfaces in 
the existing structural complexes and find if their binding modes overlap. This procedure can 
help detect druggable PPIs. Several methods have been proposed that explore different types 
of structurally homologous complexes to detect so-called multibinding interfaces [34, 35]. In 
the current study, we use the Inferred Biomolecular Interaction Server (IBIS) method [21, 
22] that clusters similar binding sites found in homologous proteins based on their sequence 
and structure conservation, and validates these using various approaches. Analysis of IBIS 
binding site clusters offers an opportunity to directly compare PPI interfaces with protein-
small molecule or with protein-peptide interfaces to identify those interfaces that can be 
potentially targeted by small molecules or peptides.
According to IBIS, there are three conserved binding site clusters between MDM2 and small 
molecules, and one conserved binding site cluster between MDM2 and p53 (PDB 1YCR 
used as a query in IBIS). IBIS allows one to compare binding sites of MDM2-p53 
interactions with the binding sites of MDM2-small molecule complexes. As can be seen in 
Fig. 1, eight sites (sites 38, 41, 42, 45, 46, 77, 80, and 84) from the second protein-small 
molecule binding site cluster extensively overlap with the MDM2-p53 binding site cluster. It 
is also clear that the third small molecule binding site cluster overlaps with MDM2-p53 only 
partially (by one to two residues) and even without activity assays, one might suggest that 
the small molecules from this cluster might not be good inhibitors of this interaction and 
therefore not relevant drugs.
3.3 Identifying Binding Hot Spot Sites
It is challenging to develop modulators of protein–protein interactions because protein–
protein interfaces are flat and lack binding pockets [37]. However, binding energy is usually 
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determined by a small number of binding “hot spots” [38]. Targeting binding hot spots in 
drug design is a simpler and more straightforward strategy. Resistance developed within the 
tumor cell subpopulations by utilizing preexisting or acquired mutations (drug resistance 
mutations) may also be predicted from examining binding hot spots.
Binding hot spots can be identified in silico, by calculating the evolutionary conservation of 
binding sites or by scanning of PPI interfaces and calculating changes in binding affinity 
upon amino acid substitutions (for example alanine scanning). This task can be achieved by 
recently developed methods MutaBind and Hot-Region. MutaBind uses molecular 
mechanics force fields, statistical potentials, and fast side-chain optimization algorithms 
[25]. The MutaBind server maps mutations on a structural protein complex, calculates the 
associated changes in binding affinity, determines the deleterious effect of a mutation, 
estimates the confidence of this prediction, and produces a mutant structural model for 
download. The HotRegion approach uses residue network topology and a statistical pairwise 
contact energy function [30].
Below is a step-by-step protocol to predict the impact of mutations on binding affinity of 
MDM2-p53 using MutaBind:
1. Open MutaBind web page (see Subheading 2) and use the PDB code 1YCR as 
an input.
2. Drag and drop “chain A” (MDM2) into the “Partner 1” box and “chain B” (p53) 
into the “Partner 2” box.
3. Select “Chain A” and binding site residues annotated by IBIS (Fig. 1b) to 
mutate; mutate them into alanine. Each mutation will be treated independently. 
Please note the residue numbering difference between PDB (MutaBind uses PDB 
numbering) and IBIS (IBIS uses the full protein sequence numbering).
Table 1 shows that 12 alanine-scanning mutations are predicted to have deleterious 
destabilizing effects on the MDM2-p53 interaction (potential binding hot spots). Among 
these potential binding hot spots, eight are responsible for the interaction with Nutlin-3a 
inhibitor, whereas nine alanine-scanning mutations are predicted to be deleterious for the 
paralogous MDMX-p53 interaction (see the next section). Overall, five evolutionarily 
conserved binding hot spots overlap between MDM2-p53, MDM2-Nutlin-3a, and MDMX-
p53 complexes are highlighted in bold fonts in Table 1.
3.4 Polypharmacology of Dual PPI Inhibitors
Drugs, including PPI inhibitors, may interact with multiple targets, inhibiting multiple PPIs 
and affecting various pathways. While cytotoxic in some cases, such polypharmacologic 
effects are desirable in other cases. For example, while targeting the p53-MDM2 interaction, 
the potency for paralogous interaction with MDMX should also be achieved. MDMX is 
structurally similar to MDM2 but lacks its p53 ubiquitin-mediated degradation activity. 
Nevertheless, MDMX can repress p53 and the effectiveness of p53-MDM2 inhibitors would 
be compromised in cells overexpressing MDMX [39]. Currently, several small-molecule 
dual p53-MDMX/MDM2 inhibitors are under development [40].
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A solution to this problem of finding dual inhibitors requires extensive sampling of protein–
small molecule binding modes in the space of similar binding interfaces of homologous 
complexes. For example, by querying IBIS with the MDMX-p53 structural complex (PDB 
3DAB), one can see that MDM2-p53 and MDMX-p53 binding interfaces are similar 
(explore the first binding site cluster for “protein-peptide” interactions in IBIS, since 
disordered p53 is classified as peptide). Figure 2 illustrates a structural superposition of 
MDM2, p53 peptide, and Nutlin-3a small molecule. According to IBIS and MutaBind, the 
major binding hot spot residues (in bold in Table 1) are retained in both paralogous proteins 
and can be targeted in designing inhibitors that disrupt both p53-MDM2 and p53-MDMX 
interactions (Table 1).
In addition to the IBIS webserver, we provide an application program interface (API), 
discussed in the sections below, to identify binding sites from homologous structures and to 
find other compounds that would bind homologous complexes (Table 2, Fig. 3). We 
illustrate a combination of IBIS APIs with PubChem APIs in an example workflow in Figs. 
4 and 5.
3.5 Incorporating Chemical Similarity and Biological Activity Data
While the biological relevance of binding interfaces via protein similarities can be assessed 
using the IBIS method, putative drug target alternatives can also be explored using the 
PubChem database [23]. PubChem is an open archive of chemical biology information 
including an expansive set of putative drug targets and bioactivity test results. PubChem 
currently contains over 92M unique chemical compounds and 3.6M substances evaluated for 
biological activity involving over 10K protein and 20K gene targets. Information can be 
obtained using the web interface, downloading from the FTP site or using programmatic 
tools as utilized in this protocol.
Similar compounds can have similar or optimized biological actions, such as the disruption 
of a protein-protein interaction binding interface. Given a query small molecule, a set of 
similar compounds can be retrieved via the proposed IBIS API, which, in turn, makes use of 
the PubChem REST API including both 2D and 3D chemical similarity searches. These two 
types of similarity searches complement each other. For 2D compound similarity, 
precomputed sets of binary fingerprints representing the constituent chemical substructures 
are compared to ensure that the key components of a query molecule are preserved. Using a 
3D similarity search, shape features of the molecules can be compared to minimize steric 
hindrance in binding pockets.
In some cases, as for example in PDB 4HG7, a co-crystallized molecule corresponds to the 
compound of interest, nutlin-3a. In other cases (e.g., 2NOU, 1T4E, 3VGB, 3U15), the bound 
small molecules may be different enough to ensure that a compound receives a unique 
identifier, but their biological activity may be similar. In order to address such cases, an 
“expansion” of query compounds using similar compounds may be very useful for 
identifying all relevant hits. We illustrate this approach in an example workflow in Figs. 4 
and 5, where an IBIS API (see also Table 2) is used to find similar compounds, and then for 
each compound a list of proteins is found that bind this compound. Finally, all protein-small 
molecule binding sites are identified for each structure in the list.
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In the search for putative drug targets, PubChem offers a wealth of pertinent information to 
help choose one alternative over another. In combination with the chemical structure search, 
the large collection of bioactivity test results in PubChem [23, 24] provide the details 
required to narrow down a list of candidates. In a first pass, molecules designated “active,” 
as defined by the original experimentalist, can be compared using filters on bioassay types 
like toxicity studies. If required, detailed analysis can be performed on individual assay 
experiments which contain large amounts of supporting data and explanations.
Finally, PubChem has collected extensive annotations for many chemical compounds. These 
include, but are not limited to, safety and hazard, pharmacological, toxicity, patent, vendor, 
interaction and pathway, classification and synonym annotations. Such annotations impact 
clinical and practical considerations like adverse reactions and purchasing. They also assist 
in making connections among existing literature references and categorizations.
3.6 Building Semiautomatic Workflows Using REST Services
Over the years, computational biology and computational chemistry communities have built 
a large number of services and resources. Some resources are integral parts of infrastructures 
provided by the large players such as EBI, NCBI, or PDB. However, integrating these 
resources in data analysis pipelines remains a tedious task that takes up significant amounts 
of project time and resources.
Some databases and web services can be combined in a modular way in workflows, thereby 
empowering users to perform complex interdisciplinary analytical processes. A workflow 
integrates a range of services to perform data-processing tasks. A service can be local or 
remote, it receives data and parameters as input, processes the request and returns the 
results. Although each service has a simple interface, complexity of workflows arises from 
the combination of services. The structure of a workflow is defined by the user and specific 
tasks. Automated workflows provide a way toward reproducible research. However, 
reproducibility becomes a complicated issue with distributed services as part of the 
workflow. Web services typically have a version prefix to make their interfaces and behavior 
backward-compatible. However, the databases are perpetually being updated and the API 
calls may return different data the next time a workflow is executed.
Pipelines and automated workflows have a long history in drug discovery, particularly with 
the advent of high-throughput screening. As robots speed up experiments at the bench, in-
silico drug-screening is accelerated by computational pipelines [41]. For instance, the 
Chemistry Development Toolkit (CDK) has plugins to both KNIME and Taverna [42, 43]. A 
popular commercial small-molecule drug discovery and protein modeling suite by 
Schrödinger is automated with KNIME. KNIME may be more suited as a data mining tool 
[44] and may therefore be more appropriate for drug discovery applications involving data 
processing in addition to automated execution.
Several primers on connecting proteins with compounds using workflows and distributed 
web services exist, for example using BindingDB and KNIME [28, 45]. One of our goals 
here is to provide a primer on data mining in drug discovery for modulating and inhibiting 
protein-protein interactions. We exemplify an approach implemented with KNIME. Taverna 
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Workflow Management System [46] is an open platform under the Apache project, 
guaranteeing a long-term development commitment. Taverna offers prebuilt packages with 
Bioinformatics services and a comprehensive online repository for open exchange of 
workflows between users—MyExperiment [47]. The latter is a social network for the 
scientific community facilitating sharing of workflows and snippets. Creators and 
maintainers of web services may choose to list them in online catalogs, making it easier for 
the users to find, annotate, and monitor distributed services. Biocatalogue [48] is the largest 
online registry of SOAP and REST Web services, and all its services can be loaded into 
Taverna Workbench or into KNIME.
Web services operate on the top of the HTTP protocol, which is used as transport for the 
web. XML-based web-services, such as SOAP and WSDL specifications, became 
widespread in computational biology and cheminformatics, and are still well maintained. 
However, standardization of web browsers and JavaScript—frontend and backend 
frameworks stimulated a transition to RESTful services using a lightweight JSON-based 
(JavaScript Object Notation) data exchange. While XML-derived data formats remain 
heavily used, many services now support JSON in addition to XML. With REST, services 
behave more like documents or resources that are uniquely identified with a URI address. 
Not only does this approach simplify the development and scalability of servers but also 
allows one to create clients in a simple way in any modern scripting language: Perl, Python, 
or JavaScript.
Table 2 describes a list of IBIS REST resources that we created to facilitate drug discovery 
workflows aimed at protein-protein interaction inhibitors. All the following resources use 
HTTPS “GET” to retrieve single entries and “POST” to submit multiple entries. Examples 
of JSON formatted results for two IBIS API calls (a) requesting inferred protein-protein 
binding sites for a given protein structure and (b) requesting similar compounds given a 
PubChem compound ID are shown in Fig. 3. These API calls may be arranged in workflows 
accepting protein and gene names, protein structure, or small molecule identifier as input. A 
listing of a Python script (Fig. 4) illustrates the workflow where output of one API call is 
passed as input to another API call, thus creating a rather complex analysis pipeline. The 
script in Fig. 4 retrieves a list of small molecule compounds similar to Nutlin-3a, identifies 
the PDB structures where any of these compounds is cocrystallized with a protein, and uses 
IBIS to retrieve description of protein-small molecule binding sites. Due to the simplicity of 
implementation of HTTP clients, the script implementing this pipeline remains relatively 
short and easy to read. In addition to programmatic access to IBIS REST API, a graphical 
representation of workflows can be created, for example using KNIME, as we illustrate in 
Fig. 5. The diagram shown in Fig. 5 implements the same workflow as in the Python script 
shown in Fig. 4.
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Fig. 1. 
Analysis of conserved binding sites using IBIS method with PDB 1YCR as a query. (a) 
MDM2 sequence annotation using Conserved Domain Database [36]; (b) Conserved protein 
binding sites between MDM2 and p53; (c) Conserved protein binding sites between MDM2 
and small molecules. Residues are numbered with respect to the full protein sequence. 
Colors of binding site residues correspond to their conservation among homologs: conserved 
residues are colored in red, less conserved in blue and nonconserved in gray
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Fig. 2. 
A superposition of MDM2-p53 (PDB code: 1YCR) and MDM2-Nutlin-3a complex (PDB 
code: 4HG7) structures
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Fig. 3. 
Examples of results of API calls: (a) to find inferred protein-protein binding sites for E3 
Ubiquitin-protein Ligase MDM2 (PDB ID 4HG7); JSON structure shows a list of binding 
site residues from a nutlin-resistant structure of MDM2 (PDB ID 4UMN) with a stapled 
peptide; (b) A list of similar small molecule compounds for nutlin-3a (PubChem compound 
ID 11433190)
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Fig. 4. 
An example of a programmatic implementation (in Python 3) of a workflow for finding 
binding sites of similar small molecules in protein structures, given a PubChem Compound 
identifier. The workflow is using three IBIS API calls described in Table 2
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Fig. 5. 
An example of a workflow diagram built in KNIME using three REST API calls (shown in 
the figure legend). The workflow identifies binding sites of similar small molecules in 
protein structures, given a PubChem Compound identifier as an input. Nodes denote 
services, while arrows show direction of information flow in the workflow. Red lines show 
assignment of variables in the flow control structures
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Table 2
Applications program interface (API) to extract and process data on protein-protein and protein-small 
molecule interactions
URI Description of retrieved results
/structures/protein/<PROTEIN> PDB and chain identifiers given a human gene name or a UniProt protein name
/structures/compound/<CID> PDB identifiers containing a given PubChem compound
/sites/obs/protein/pdb/<PDB>[/<CHAIN>] Observed protein-protein binding site residues given a PDB identifier and an optional chain 
identifier. Each binding site specifies two interacting chains, the interacting domains and a list 
of residues
/sites/obs/compound/pdb/<PDB>[/<CHAIN>] Observed protein-small molecule binding sites for each compound in a given protein structure
/sites/obs/peptide/pdb/<PDB>[/<CHAIN>] Observed protein-peptide binding sites given a protein structure. The interacting peptide 
sequence is returned as well
/sites/obs/compound/compound/<CID> Proteins and observed protein-small molecule binding sites given a compound of interest
/sites/inf/protein/pdb/<PDB>[/<CHAIN>] Inferred protein-protein binding site residues given a protein structure
/sites/inf/peptide/pdb/<PDBID>[/<CHAIN>] Inferred protein-peptide binding site residues given a PDB and an optional chain identifier
/sites/inf/compound/pdb/<PDB>[/<CHAIN>] Inferred protein-small molecule binding site residues given a protein structure
/compounds/similar/compound/<CID> Similar small molecule compounds given a small molecule. Performs both 2D fingerprint and 
3D fast searches
All IBIS API resources have a prefix “https://www.ncbi.nlm.nih.gov/research/ibis-api/rest/v1,” followed by more specific parts of the URI. 
Required parameters are specified in angle brackets, while optional parameters are specified in square brackets. The following parameters specified 
in angle brackets are used: <CID> PubChem compound identifier; <PDB> <CHAIN> PDB and chain identifiers. Additional instructions are 
available online at https://www.ncbi.nlm.nih.gov/research/ibis-api/
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